Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
Targeted alpha-particle emitters are promising therapeutics for micrometastatic disease. Actinium-225 has a 10-day half-life and generates a total of four alpha-particles per parent decay rendering (225)Ac an attractive candidate for alpha-therapy. For cancer cells with low surface expression levels of molecular targets, targeting strategies of (225)Ac using radiolabeled carriers of low specific radioactivities (such as antibodies) may not deliver enough alpha-particle emitters at the targeted cancer cells to result in killing. We previously proposed and showed using passive (225)Ac entrapment that liposomes can stably retain encapsulated (225)Ac for long time periods, and that antibody-conjugated liposomes (immunoliposomes) with encapsulated (225)Ac can specifically target and become internalized by cancer cells. However, to enable therapeutic use of (225)Ac-containing liposomes, high activities of (225)Ac need to be stably encapsulated into liposomes. In this study, various conditions for active loading of (225)Ac in preformed liposomes (ionophore-type, encapsulated buffer solution, and loading time) were evaluated, and liposomes with up to 73 +/- 9% of the initial activity of (225)Ac (0.2-200 microCi) were developed. Retention of radioactive contents by liposomes was evaluated at 37 degrees C in phosphate buffer and in serum-supplemented media. The main fraction of released (225)Ac from liposomes occurs within the first two hours of incubation. Beyond this two hour point, the encapsulated radioactivity is released from liposomes slowly with an approximate half-life of the order of several days. In some cases, after 30 days, (225)Ac retention as high as 81 +/- 7% of the initially encapsulated radioactivity was achieved. The (225)Ac loading protocol was also applied to immunoliposome loading without significant loss of targeting efficacy. Liposomes with surface-conjugated antibodies that are loaded with (225)Ac overcome the limitations of low specific activity for molecular carriers and are expected to be therapeutically useful against tumor cells having a low antigen density.
Chang
Min-Yuan
MY
Othmer-Jacobs Department of Chemical and Biological Engineering, Polytechnic University, 6 MetroTech Center, Brooklyn, New York 11201, USA.
Seideman
Jonathan
J
Sofou
Stavroula
S
D000186:Actinium / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use*; D000512:Alpha Particles / Q000627:therapeutic use; D000818:Animals; D002021:Buffers; D045744:Cell Line, Tumor; D004355:Drug Stability; D006361:Heating; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry; D007476:Ionophores / Q000737:chemistry; D008051:Lipid Bilayers / Q000378:metabolism; D008081:Liposomes / Q000737:chemistry*; D051379:Mice; D009362:Neoplasm Metastasis / Q000532:radiotherapy*; D010316:Particle Size; D010539:Permeability; D011092:Polyethylene Glycols / Q000737:chemistry; D013696:Temperature; D013997:Time Factors
D002021:Buffers; D018796:Immunoconjugates; D007476:Ionophores; D008051:Lipid Bilayers; D008081:Liposomes; D011092:Polyethylene Glycols; D000186:Actinium